Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Patrick R. O'neil sold 1,207 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the completion of the sale, the executive vice president now owns 56,245 shares in the company, valued at $1,819,525.75. The trade was a 2.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Ionis Pharmaceuticals Trading Up 0.0 %
IONS stock traded up $0.02 during trading on Thursday, hitting $31.78. 239,815 shares of the company traded hands, compared to its average volume of 1,644,963. The company has a 50-day moving average of $33.32 and a 200-day moving average of $37.98. The firm has a market capitalization of $5.05 billion, a PE ratio of -10.46 and a beta of 0.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals, Inc. has a 1 year low of $30.23 and a 1 year high of $52.34.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. The business had revenue of $227.00 million during the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. Ionis Pharmaceuticals's quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.12 EPS. Analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms have weighed in on IONS. Citigroup lowered their price target on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Piper Sandler decreased their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Finally, StockNews.com lowered Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $60.00.
View Our Latest Stock Report on Ionis Pharmaceuticals
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of IONS. Capital World Investors raised its position in Ionis Pharmaceuticals by 46.5% during the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company's stock valued at $400,831,000 after purchasing an additional 3,637,041 shares during the last quarter. Norges Bank bought a new position in shares of Ionis Pharmaceuticals in the 4th quarter worth approximately $59,948,000. Vanguard Group Inc. increased its position in Ionis Pharmaceuticals by 9.4% during the 4th quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock valued at $575,880,000 after buying an additional 1,416,781 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Ionis Pharmaceuticals in the 4th quarter worth $20,801,000. Finally, Orbimed Advisors LLC lifted its position in Ionis Pharmaceuticals by 21.2% during the fourth quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company's stock valued at $98,494,000 after purchasing an additional 492,900 shares in the last quarter. Institutional investors own 93.86% of the company's stock.
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Recommended Stories
Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
